Key Points
- Insider sale: Thomas Lynch sold 20,000 Billiontoone shares for approximately $2.0 million under a Rule 10b5-1 trading plan, reducing his ownership by 96.62% to 700 shares.
- Stock and financial performance: BLLN opened at $98.51, with a $61.96–$150.44 one-year range and a $4.65 billion market capitalization. The company met quarterly earnings expectations at $0.15 per share and reported $109.45 million in revenue.
- Analyst sentiment: Wall Street’s consensus rating is Hold, with an average price target of $125.88; seven analysts rate the stock Buy, two Hold, and two Sell.
Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) insider Thomas Lynch sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $99.99, for a total transaction of $1,999,800.00. Following the transaction, the insider owned 700 shares of the company's stock, valued at approximately $69,993. This represents a 96.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Billiontoone Price Performance
Shares of NASDAQ:BLLN opened at $98.51 on Friday. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $150.44. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. The company has a market cap of $4.65 billion and a price-to-earnings ratio of 140.73. The firm has a 50 day simple moving average of $112.07 and a 200 day simple moving average of $95.79.
Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting analysts' consensus estimates of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. Research analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
BLLN has been the topic of a number of research reports. Wall Street Zen lowered Billiontoone from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Canaccord Genuity Group began coverage on Billiontoone in a research note on Wednesday, September 2nd. They set a "buy" rating and a $120.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Billiontoone from $145.00 to $130.00 and set an "overweight" rating on the stock in a research note on Thursday, August 6th. Zacks Research downgraded Billiontoone from a "hold" rating to a "strong sell" rating in a research note on Monday, August 31st. Finally, BTIG Research lowered their price objective on Billiontoone from $142.00 to $130.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $125.88.
Check Out Our Latest Stock Analysis on BLLN
Institutional Trading of Billiontoone
Several institutional investors have recently modified their holdings of BLLN. UBS Group AG acquired a new stake in Billiontoone in the fourth quarter valued at $2,586,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone during the 4th quarter worth about $82,000. Geode Capital Management LLC acquired a new position in Billiontoone during the 4th quarter worth about $6,716,000. Seven Grand Managers LLC bought a new stake in shares of Billiontoone in the 4th quarter valued at about $2,046,000. Finally, Norges Bank bought a new stake in shares of Billiontoone in the 4th quarter valued at about $818,000.
About Billiontoone
(
Get Free Report)
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
